Merus NV (NASDAQ:MRUS) has been given an average recommendation of “Buy” by the nine brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $24.00.
Several equities research analysts have weighed in on the company. Zacks Investment Research raised Merus from a “sell” rating to a “hold” rating in a research report on Friday, February 7th. ValuEngine lowered Merus from a “hold” rating to a “sell” rating in a research report on Thursday, January 16th. BidaskClub raised Merus from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Guggenheim assumed coverage on Merus in a research report on Wednesday, November 20th. They issued a “buy” rating and a $25.00 target price on the stock.
Shares of MRUS opened at $18.61 on Friday. The business’s fifty day moving average price is $16.11 and its 200 day moving average price is $16.39. Merus has a 12-month low of $11.00 and a 12-month high of $20.95. The stock has a market capitalization of $435.61 million, a PE ratio of -14.43 and a beta of 0.10.
In other Merus news, major shareholder Bvf Partners L. P/Il purchased 278,730 shares of the stock in a transaction dated Thursday, January 16th. The shares were bought at an average cost of $16.15 per share, with a total value of $4,501,489.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Value Fund L. P. Biotechnology purchased 83,962 shares of the stock in a transaction dated Monday, January 13th. The shares were acquired at an average cost of $15.60 per share, for a total transaction of $1,309,807.20. The disclosure for this purchase can be found here.
Several institutional investors and hedge funds have recently modified their holdings of MRUS. UBS Group AG acquired a new position in shares of Merus during the fourth quarter valued at $30,000. Marshall Wace North America L.P. acquired a new position in shares of Merus during the fourth quarter valued at $34,000. Tower Research Capital LLC TRC acquired a new position in shares of Merus during the third quarter valued at $48,000. California Public Employees Retirement System increased its holdings in shares of Merus by 14.4% during the fourth quarter. California Public Employees Retirement System now owns 11,441 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 1,441 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in shares of Merus by 29.5% during the fourth quarter. Acadian Asset Management LLC now owns 12,035 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,740 shares during the period. 50.77% of the stock is currently owned by institutional investors.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Featured Article: Learning About the VIX – Volatility Index
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.